These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 26764156)

  • 1. Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials.
    Berry-Kravis E; Des Portes V; Hagerman R; Jacquemont S; Charles P; Visootsak J; Brinkman M; Rerat K; Koumaras B; Zhu L; Barth GM; Jaecklin T; Apostol G; von Raison F
    Sci Transl Med; 2016 Jan; 8(321):321ra5. PubMed ID: 26764156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents.
    Hagerman R; Jacquemont S; Berry-Kravis E; Des Portes V; Stanfield A; Koumaras B; Rosenkranz G; Murgia A; Wolf C; Apostol G; von Raison F
    Sci Rep; 2018 Nov; 8(1):16970. PubMed ID: 30451888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.
    Jacquemont S; Curie A; des Portes V; Torrioli MG; Berry-Kravis E; Hagerman RJ; Ramos FJ; Cornish K; He Y; Paulding C; Neri G; Chen F; Hadjikhani N; Martinet D; Meyer J; Beckmann JS; Delange K; Brun A; Bussy G; Gasparini F; Hilse T; Floesser A; Branson J; Bilbe G; Johns D; Gomez-Mancilla B
    Sci Transl Med; 2011 Jan; 3(64):64ra1. PubMed ID: 21209411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of mavoglurant and its potential for the treatment of fragile X syndrome.
    Gomez-Mancilla B; Berry-Kravis E; Hagerman R; von Raison F; Apostol G; Ufer M; Gasparini F; Jacquemont S
    Expert Opin Investig Drugs; 2014 Jan; 23(1):125-34. PubMed ID: 24251408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of mavoglurant on visual attention and pupil reactivity while viewing photographs of faces in Fragile X Syndrome.
    Hessl D; Harvey D; Sansone S; Crestodina C; Chin J; Joshi R; Hagerman RJ; Berry-Kravis E
    PLoS One; 2019; 14(1):e0209984. PubMed ID: 30653533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results.
    Youssef EA; Berry-Kravis E; Czech C; Hagerman RJ; Hessl D; Wong CY; Rabbia M; Deptula D; John A; Kinch R; Drewitt P; Lindemann L; Marcinowski M; Langland R; Horn C; Fontoura P; Santarelli L; Quiroz JA;
    Neuropsychopharmacology; 2018 Feb; 43(3):503-512. PubMed ID: 28816242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX).
    Berry-Kravis E; Hagerman R; Budimirovic D; Erickson C; Heussler H; Tartaglia N; Cohen J; Tassone F; Dobbins T; Merikle E; Sebree T; Tich N; Palumbo JM; O'Quinn S
    J Neurodev Disord; 2022 Nov; 14(1):56. PubMed ID: 36434514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study.
    Bailey DB; Berry-Kravis E; Wheeler A; Raspa M; Merrien F; Ricart J; Koumaras B; Rosenkranz G; Tomlinson M; von Raison F; Apostol G
    J Neurodev Disord; 2016; 8():1. PubMed ID: 26855682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome.
    Berry-Kravis E; Sumis A; Hervey C; Nelson M; Porges SW; Weng N; Weiler IJ; Greenough WT
    J Dev Behav Pediatr; 2008 Aug; 29(4):293-302. PubMed ID: 18698192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice.
    Gantois I; Pop AS; de Esch CE; Buijsen RA; Pooters T; Gomez-Mancilla B; Gasparini F; Oostra BA; D'Hooge R; Willemsen R
    Behav Brain Res; 2013 Feb; 239():72-9. PubMed ID: 23142366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial.
    Berry-Kravis E; Krause SE; Block SS; Guter S; Wuu J; Leurgans S; Decle P; Potanos K; Cook E; Salt J; Maino D; Weinberg D; Lara R; Jardini T; Cogswell J; Johnson SA; Hagerman R
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):525-40. PubMed ID: 17069542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting mGluR5 activity by AFQ056/Mavoglurant rescues circuit-specific functional connectivity in Fmr1 knockout mice.
    Zerbi V; Markicevic M; Gasparini F; Schroeter A; Rudin M; Wenderoth N
    Neuroimage; 2019 May; 191():392-402. PubMed ID: 30807820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome.
    Scharf SH; Jaeschke G; Wettstein JG; Lindemann L
    Curr Opin Pharmacol; 2015 Feb; 20():124-34. PubMed ID: 25488569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro.
    Tabolacci E; Pirozzi F; Gomez-Mancilla B; Gasparini F; Neri G
    BMC Med Genet; 2012 Mar; 13():13. PubMed ID: 22397687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome.
    Heussler H; Cohen J; Silove N; Tich N; Bonn-Miller MO; Du W; O'Neill C; Sebree T
    J Neurodev Disord; 2019 Aug; 11(1):16. PubMed ID: 31370779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome.
    Leigh MJ; Nguyen DV; Mu Y; Winarni TI; Schneider A; Chechi T; Polussa J; Doucet P; Tassone F; Rivera SM; Hessl D; Hagerman RJ
    J Dev Behav Pediatr; 2013 Apr; 34(3):147-55. PubMed ID: 23572165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome.
    de la Torre R; de Sola S; Farré M; Xicota L; Cuenca-Royo A; Rodriguez J; León A; Langohr K; Gomis-González M; Hernandez G; Esteba S; Del Hoyo L; Sánchez-Gutiérrez J; Cortés MJ; Ozaita A; Espadaler JM; Novell R; Martínez-Leal R; Milá M; Dierssen M;
    Clin Nutr; 2020 Feb; 39(2):378-387. PubMed ID: 30962103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study.
    Çaku A; Pellerin D; Bouvier P; Riou E; Corbin F
    Am J Med Genet A; 2014 Nov; 164A(11):2834-42. PubMed ID: 25258112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study.
    Budimirovic DB; Dominick KC; Gabis LV; Adams M; Adera M; Huang L; Ventola P; Tartaglia NR; Berry-Kravis E
    Front Pharmacol; 2021; 12():757825. PubMed ID: 34690787
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial.
    Berry-Kravis EM; Hessl D; Rathmell B; Zarevics P; Cherubini M; Walton-Bowen K; Mu Y; Nguyen DV; Gonzalez-Heydrich J; Wang PP; Carpenter RL; Bear MF; Hagerman RJ
    Sci Transl Med; 2012 Sep; 4(152):152ra127. PubMed ID: 22993294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.